Patents by Inventor Wenxia Zhou

Wenxia Zhou has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of tadalafil as protein arginine methyltransferase (PRMT5) inhibitor
    Patent number: 11369602
    Abstract: The present invention provides use of Tadalafil as a protein arginine methyltransferase 5 (PRMT5) inhibitor. The present invention finds out that Tadalafil is a PRMT5 inhibitor by virtually screening active compounds targeting PRMT5 based on crystal structure and information about active sites of PRMT5. The present invention not only confirms that Tadalafil can inhibit an enzymatic activity of PRMT5, but also confirms that Tadalafil alone can inhibit tumor growth in breast cancer and improve sensitivity to chemotherapy for breast cancer.
    Type: Grant
    Filed: August 2, 2020
    Date of Patent: June 28, 2022
    Assignee: Fourth Military Medical University of People's Liberation Army
    Inventors: Jian Zhang, Ying Wu, Rui Ling, Suning Chen, Lu Han, Wenxia Zhou
  • USE OF TADALAFIL AS PROTEIN ARGININE METHYLTRANSFERASE (PRMT5) INHIBITOR
    Publication number: 20210052581
    Abstract: The present invention provides use of Tadalafil as a protein arginine methyltransferase 5 (PRMT5) inhibitor. The present invention finds out that Tadalafil is a PRMT5 inhibitor by virtually screening active compounds targeting PRMT5 based on crystal structure and information about active sites of PRMT5. The present invention not only confirms that Tadalafil can inhibit an enzymatic activity of PRMT5, but also confirms that Tadalafil alone can inhibit tumor growth in breast cancer and improve sensitivity to chemotherapy for breast cancer.
    Type: Application
    Filed: August 2, 2020
    Publication date: February 25, 2021
    Inventors: Jian ZHANG, Ying Wu, Rui Ling, Suning Chen, Lu Han, Wenxia Zhou
  • Preparation method of nanosheet nitrogen-containing porous carbon material
    Publication number: 20160145168
    Abstract: A preparation method of a nanosheet nitrogen-containing porous carbon material includes steps of: dissolving alkali and water-soluble amine-containing compound in water, forming an aqueous solution; adding cellulose or a derivative thereof into the aqueous solution; after mixing and drying, obtaining a crystal composite of the alkali and the water-soluble amine-containing compound, wrapped by the cellulose or the derivative thereof; carbonizing the crystal composite under nitrogen gas flow; washing a crabonized product; and obtaining the nanosheet nitrogen-containing porous carbon material. Through changing a proportion among the alkali, the water-soluble amine-containing compound and the cellulose or the derivative thereof, a specific surface area, pore structure, nitrogen content and thickness of the nanosheet nitrogen-containing porous carbon material are adjusted.
    Type: Application
    Filed: May 14, 2015
    Publication date: May 26, 2016
    Inventors: Tuoping Hu, Wenzhong Shen, Hongyan Song, Jinquan Wei, Wenxia Zhou, Weiguang Ping, Xi Chen
  • Polyethlene glycol modifications of thymosin alpha-1
    Patent number: 8080522
    Abstract: Polyethylene glycol modifications of thymosin alpha 1 (T&agr; 1-PEGs), their preparation process, the medicine composition containing them, and their application in the medicine for preventing and treating diseases related with immune deficiency and hypoimmunity, including hepatitis B, hepatitis C, hepatoma, malignant melanoma, non-small cell lung cancer, SARS, and AIDS etc.
    Type: Grant
    Filed: November 11, 2006
    Date of Patent: December 20, 2011
    Assignee: Institute of Pharmacology and Toxicology Academy of Military Mecical Sciences, P.L.A., China
    Inventors: Keliang Liu, Jiankun Qie, Jinbo Ma, Jianquan Zheng, Sijian Dong, Wenxia Zhou, Chunhui Qi
  • POLYETHLENE GLYCOL MODIFICATIONS OF THYMOSIN ALPHA-1
    Publication number: 20090221487
    Abstract: Polyethylene glycol modifications of thymosin alpha 1 (T&agr; 1-PEGs), their preparation process, the medicine composition containing them, and their application in the medicine for preventing and treating diseases related with immune deficiency and hypoimmunity, including hepatitis B, hepatitis C, hepatoma, malignant melanoma, non-small cell lung cancer, SARS, and AIDS etc.
    Type: Application
    Filed: November 11, 2006
    Publication date: September 3, 2009
    Applicant: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China
    Inventors: Keliang Liu, Jiankun Qie, Jinbo Ma, Jianquan Zheng, Sijian Dong, Sijian Dong, Wenxia Zhou, Chunhui Qi